Does the media prefer ADMA or ANIP?

In the previous week, ADMA Biologics had 33 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 41 mentions for ADMA Biologics and 8 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.73 beat ADMA Biologics' score of 0.09 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 3 Very Positive mention(s) 1 Positive mention(s) 34 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral ANI Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ANVS or ANIP?

In the previous week, ANI Pharmaceuticals had 6 more articles in the media than Annovis Bio. MarketBeat recorded 8 mentions for ANI Pharmaceuticals and 2 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 1.34 beat ANI Pharmaceuticals' score of 0.73 indicating that Annovis Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annovis Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ANI Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ANIP or RYTM?

In the previous week, Rhythm Pharmaceuticals had 8 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 16 mentions for Rhythm Pharmaceuticals and 8 mentions for ANI Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.11 beat ANI Pharmaceuticals' score of 0.73 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer MIRM or ANIP?

In the previous week, Mirum Pharmaceuticals had 1 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 9 mentions for Mirum Pharmaceuticals and 8 mentions for ANI Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.34 beat ANI Pharmaceuticals' score of 0.73 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ANI Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, LNTH or ANIP?

Lantheus has higher revenue and earnings than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.27 $233.56M $4.15 24.36 ANI Pharmaceuticals $883.37M 2.04 $78.34M $3.95 20.05

Does the media refer more to LNTH or ANIP?

In the previous week, Lantheus had 19 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 27 mentions for Lantheus and 8 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.73 beat Lantheus' score of 0.26 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 8 Very Positive mention(s) 3 Positive mention(s) 11 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral ANI Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ANI Pharmaceuticals (ANIP) Competitors

$79.20 -0.86 (-1.07%)

Closing price 04:00 PM Eastern

Extended Trading

$79.32 +0.12 (+0.15%)

As of 07:34 PM Eastern

Compare

ANIP vs. ADMA, ANVS, RYTM, MIRM, and LNTH

Should you buy ANI Pharmaceuticals stock or one of its competitors? MarketBeat compares ANI Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ANI Pharmaceuticals include ADMA Biologics (ADMA), Annovis Bio (ANVS), Rhythm Pharmaceuticals (RYTM), Mirum Pharmaceuticals (MIRM), and Lantheus (LNTH).

How does ANI Pharmaceuticals compare to ADMA Biologics?

ADMA Biologics (NASDAQ:ADMA) and ANI Pharmaceuticals (NASDAQ:ANIP) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

ADMA Biologics has a net margin of 32.43% compared to ANI Pharmaceuticals' net margin of 9.98%. ADMA Biologics' return on equity of 39.98% beat ANI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.43%	39.98%	28.08%
ANI Pharmaceuticals	9.98%	27.51%	10.02%

ADMA Biologics has higher earnings, but lower revenue than ANI Pharmaceuticals. ADMA Biologics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	4.05	$146.93M	$0.68	13.10
ANI Pharmaceuticals	$883.37M	2.04	$78.34M	$3.95	20.05

In the previous week, ADMA Biologics had 33 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 41 mentions for ADMA Biologics and 8 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.73 beat ADMA Biologics' score of 0.09 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	3 Very Positive mention(s)	1 Positive mention(s)	34 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
ANI Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ADMA Biologics has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market.

75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 3.9% of ADMA Biologics shares are owned by insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

ADMA Biologics presently has a consensus target price of $18.67, suggesting a potential upside of 109.50%. ANI Pharmaceuticals has a consensus target price of $105.00, suggesting a potential upside of 32.58%. Given ADMA Biologics' higher possible upside, equities analysts plainly believe ADMA Biologics is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
ANI Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

ADMA Biologics and ANI Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Annovis Bio?

Annovis Bio (NYSE:ANVS) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

ANI Pharmaceuticals has a net margin of 9.98% compared to Annovis Bio's net margin of 0.00%. ANI Pharmaceuticals' return on equity of 27.51% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-318.08%	-215.47%
ANI Pharmaceuticals	9.98%	27.51%	10.02%

Annovis Bio currently has a consensus price target of $11.67, suggesting a potential upside of 522.22%. ANI Pharmaceuticals has a consensus price target of $105.00, suggesting a potential upside of 32.58%. Given Annovis Bio's higher possible upside, research analysts clearly believe Annovis Bio is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
ANI Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are held by institutional investors. 20.8% of Annovis Bio shares are held by insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

ANI Pharmaceuticals has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A
ANI Pharmaceuticals	$883.37M	2.04	$78.34M	$3.95	20.05

In the previous week, ANI Pharmaceuticals had 6 more articles in the media than Annovis Bio. MarketBeat recorded 8 mentions for ANI Pharmaceuticals and 2 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 1.34 beat ANI Pharmaceuticals' score of 0.73 indicating that Annovis Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annovis Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ANI Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Annovis Bio has a beta of 1.25, indicating that its share price is 25% more volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market.

Summary

ANI Pharmaceuticals beats Annovis Bio on 11 of the 16 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Rhythm Pharmaceuticals?

ANI Pharmaceuticals (NASDAQ:ANIP) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

In the previous week, Rhythm Pharmaceuticals had 8 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 16 mentions for Rhythm Pharmaceuticals and 8 mentions for ANI Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.11 beat ANI Pharmaceuticals' score of 0.73 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	6 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

ANI Pharmaceuticals has a net margin of 9.98% compared to Rhythm Pharmaceuticals' net margin of -93.33%. ANI Pharmaceuticals' return on equity of 27.51% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	9.98%	27.51%	10.02%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

ANI Pharmaceuticals currently has a consensus target price of $105.00, indicating a potential upside of 32.58%. Rhythm Pharmaceuticals has a consensus target price of $138.73, indicating a potential upside of 31.15%. Given ANI Pharmaceuticals' higher probable upside, equities analysts plainly believe ANI Pharmaceuticals is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 8.1% of ANI Pharmaceuticals shares are owned by company insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ANI Pharmaceuticals has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37M	2.04	$78.34M	$3.95	20.05
Rhythm Pharmaceuticals	$189.76M	38.20	-$196.54M	-$3.13	N/A

ANI Pharmaceuticals has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market.

Summary

ANI Pharmaceuticals beats Rhythm Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and ANI Pharmaceuticals (NASDAQ:ANIP) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

ANI Pharmaceuticals has a net margin of 9.98% compared to Mirum Pharmaceuticals' net margin of -140.24%. ANI Pharmaceuticals' return on equity of 27.51% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
ANI Pharmaceuticals	9.98%	27.51%	10.02%

In the previous week, Mirum Pharmaceuticals had 1 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 9 mentions for Mirum Pharmaceuticals and 8 mentions for ANI Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.34 beat ANI Pharmaceuticals' score of 0.73 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ANI Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market.

ANI Pharmaceuticals has higher revenue and earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	12.20	-$23.36M	-$13.61	N/A
ANI Pharmaceuticals	$883.37M	2.04	$78.34M	$3.95	20.05

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Mirum Pharmaceuticals presently has a consensus target price of $143.40, suggesting a potential upside of 37.45%. ANI Pharmaceuticals has a consensus target price of $105.00, suggesting a potential upside of 32.58%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Mirum Pharmaceuticals is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
ANI Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Mirum Pharmaceuticals beats ANI Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Lantheus?

Lantheus (NASDAQ:LNTH) and ANI Pharmaceuticals (NASDAQ:ANIP) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Lantheus has a net margin of 18.05% compared to ANI Pharmaceuticals' net margin of 9.98%. Lantheus' return on equity of 29.32% beat ANI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
ANI Pharmaceuticals	9.98%	27.51%	10.02%

Lantheus has higher revenue and earnings than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.27	$233.56M	$4.15	24.36
ANI Pharmaceuticals	$883.37M	2.04	$78.34M	$3.95	20.05

Lantheus has a beta of -0.03, suggesting that its stock price is 103% less volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

Lantheus currently has a consensus price target of $108.11, suggesting a potential upside of 6.92%. ANI Pharmaceuticals has a consensus price target of $105.00, suggesting a potential upside of 32.58%. Given ANI Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe ANI Pharmaceuticals is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	8 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
ANI Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Lantheus had 19 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 27 mentions for Lantheus and 8 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.73 beat Lantheus' score of 0.26 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	8 Very Positive mention(s)	3 Positive mention(s)	11 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
ANI Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 1.7% of Lantheus shares are owned by company insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Lantheus beats ANI Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get ANI Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANIP vs. The Competition

Export

Metric	ANI Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.82B	$11.51B	$6.85B	$12.76B
Dividend Yield	N/A	2.73%	2.59%	9.85%
P/E Ratio	20.05	664.20	220.67	22.98
Price / Sales	2.04	730.98	590.98	93.54
Price / Cash	8.06	71.54	72.11	49.39
Price / Book	3.30	10.83	12.95	6.11
Net Income	$78.34M	$2.81B	$3.48B	$347.58M
7 Day Performance	-2.27%	1.83%	2.59%	3.17%
1 Month Performance	-7.94%	-3.14%	-2.79%	-2.06%
1 Year Performance	21.05%	154.81%	64.29%	21.19%

ANI Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANIP ANI Pharmaceuticals	4.0514 of 5 stars	$79.20 -1.1%	$105.00 +32.6%	+25.2%	$1.82B	$883.37M	20.05	600	Upcoming Earnings
ADMA ADMA Biologics	4.6056 of 5 stars	$8.48 +2.5%	$18.67 +120.1%	-54.8%	$1.92B	$510.17M	12.47	530	Trending News Upcoming Earnings
ANVS Annovis Bio	3.54 of 5 stars	$1.67 +0.3%	$11.67 +600.7%	-31.3%	$57.51M	N/A	N/A	3	News Coverage Upcoming Earnings
RYTM Rhythm Pharmaceuticals	3.4379 of 5 stars	$106.13 +3.9%	$138.73 +30.7%	+16.4%	$7.00B	$189.76M	N/A	140	Trending News Earnings Report
MIRM Mirum Pharmaceuticals	3.3916 of 5 stars	$114.20 +1.0%	$143.40 +25.6%	+101.1%	$6.89B	$521.31M	N/A	140	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANIP) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ANI Pharmaceuticals (ANIP) Competitors

ANIP vs. ADMA, ANVS, RYTM, MIRM, and LNTH

How does ANI Pharmaceuticals compare to ADMA Biologics?

Summary

How does ANI Pharmaceuticals compare to Annovis Bio?

Summary

How does ANI Pharmaceuticals compare to Rhythm Pharmaceuticals?

Summary

How does ANI Pharmaceuticals compare to Mirum Pharmaceuticals?

Summary

How does ANI Pharmaceuticals compare to Lantheus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIP vs. The Competition

ANI Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ANI Pharmaceuticals (ANIP) Competitors

ANIP vs. ADMA, ANVS, RYTM, MIRM, and LNTH

How does ANI Pharmaceuticals compare to ADMA Biologics?

Is ADMA or ANIP more profitable?

Which has preferable valuation & earnings, ADMA or ANIP?

Does the media prefer ADMA or ANIP?

Which has more risk and volatility, ADMA or ANIP?

Do institutionals & insiders have more ownership in ADMA or ANIP?

Do analysts prefer ADMA or ANIP?

Summary

How does ANI Pharmaceuticals compare to Annovis Bio?

Is ANVS or ANIP more profitable?

Do analysts prefer ANVS or ANIP?

Do institutionals & insiders have more ownership in ANVS or ANIP?

Which has higher earnings & valuation, ANVS or ANIP?

Does the media prefer ANVS or ANIP?

Which has more risk and volatility, ANVS or ANIP?

Summary

How does ANI Pharmaceuticals compare to Rhythm Pharmaceuticals?

Does the media favor ANIP or RYTM?

Is ANIP or RYTM more profitable?

Do analysts rate ANIP or RYTM?

Do institutionals & insiders hold more shares of ANIP or RYTM?

Which has better valuation & earnings, ANIP or RYTM?

Which has more risk and volatility, ANIP or RYTM?

Summary

How does ANI Pharmaceuticals compare to Mirum Pharmaceuticals?

Is MIRM or ANIP more profitable?

Does the media prefer MIRM or ANIP?

Which has more volatility and risk, MIRM or ANIP?

Which has stronger valuation and earnings, MIRM or ANIP?

Do insiders & institutionals hold more shares of MIRM or ANIP?

Do analysts prefer MIRM or ANIP?

Summary

How does ANI Pharmaceuticals compare to Lantheus?

Is LNTH or ANIP more profitable?

Which has stronger earnings and valuation, LNTH or ANIP?

Which has more volatility and risk, LNTH or ANIP?

Do analysts recommend LNTH or ANIP?

Does the media refer more to LNTH or ANIP?

Do institutionals and insiders have more ownership in LNTH or ANIP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIP vs. The Competition

ANI Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools